The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp

Table 1

Characteristics of rats in the four groups at the end of study.

	C; ()	C + E; ()	D; ()	D + E; ()
Body weight (g)	531.9 ± 37.6	474.3 ± 24.9	468.2 ± 29.0	397.6 ±
FBG (mmol/L)	5.57 ± 0.31	4.25 ± 0.55^#	15.10 ± 1.73	9.48 ± 1.61
FINS (μIu/mL)	12.84 ± 5.26	15.00 ± 5.55	29.09 ± 3.61	18.86 ± 2.48
HOMA-IR	3.19 ± 1.38	2.79 ± 0.94	18.40 ± 3.84	7.54 ± 1.58
ISI	−4.15 ± 0.61	−4.09 ± 0.35	−6.01 ± 0.21	−5.12 ± 0.21
TC (mmol/L)	1.19 ± 0.23	1.02 ± 0.14	1.85 ± 0.16	1.61 ± 0.11
TG (mmol/L)	0.12 ± 0.04	0.19 ± 0.06	0.63 ± 0.08	0.44 ± 0.07
LDL (mmol/L)	0.23 ± 0.04	0.20 ± 0.05	0.61 ± 0.11	0.43 ± 0.13

C: nondiabetic control; C + E: nondiabetic + exenatide; D: diabetic; D + E, diabetic + exenatide.
FBG: fasting blood glucose; FINS: fasting plasma insulin; ISI: insulin sensitivity index.
Data are presented as mean ± SD.
, compared with normal rats (C).
compared with normal rats treated with exenatide (C + E).
, compared with diabetic rats treated with vehicle (D).